Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse.
Alba. Maria M; Fintini. Danilo D; Bowers. Cyril Y CY; Parlow. A F AF; Salvatori. Roberto R
Key Findings
- GHRP-2 did not stimulate somatotroph cell proliferation or GH secretion in GHRH‑knockout mice.
- Long‑term GHRP-2 treatment failed to promote longitudinal growth in these mice.
- Treated mice gained more total body weight due to worsening of the typical GHD‑related body‑composition changes.
Practical Outcomes
- For biohackers, this study suggests that GHRP-2’s growth‑boosting effects depend on a functional GHRH system; it won’t overcome a true GH deficiency. In healthy or mildly GH‑deficient individuals, the peptide may still work, but it isn’t a shortcut for major growth or body‑composition improvements. Use caution and don’t expect dramatic size or muscle gains from GHRP-2 alone if your GH axis is impaired.
Summary
In mice that lack the natural hormone that tells the pituitary to release growth hormone (GHRH), giving the peptide GHRP-2 for six weeks did not make them grow taller, increase growth‑hormone levels, or boost pituitary cell growth. The mice actually gained more weight because their body‑composition got worse, showing that GHRP-2 can’t fix severe growth‑hormone deficiency on its own.
Abstract
Growth hormone (GH) secretagogues (GHS) stimulate GH secretion in vivo in humans and in animals. They act on the ghrelin receptor, expressed in both the hypothalamus and the pituitary. It is unknown whether GHSs act predominantly by increasing the release of hypothalamic GH-releasing hormone (GHRH) or by acting directly on the somatotroph cells. We studied whether a potent GHS could stimulate growth in the absence of endogenous GHRH. To this end, we used GHRH knockout (GHRH-KO) mice. These animals have proportionate dwarfism due to severe GH deficiency (GHD) and pituitary hypoplasia due to reduced somatotroph cell mass. We treated male GHRH-KO mice for 6 wk (from week 1 to week 7 of age) with GH-releasing peptide-2 (GHRP-2, 10 microg s.c. twice a day). Chronic treatment with GHRP-2 failed to stimulate somatotroph cell proliferation and GH secretion and to promote longitudinal growth. GHRP-2-treated mice showed an increase in total body weight compared with placebo-treated animals, due to worsening of the body composition alterations typical of GHD animals. These data demonstrate that GHRP-2 failed to reverse the severe GHD caused by lack of GHRH.
Study Information
pubmed
2005
2005-06-28T00:00:00.000Z
10.1152/ajpendo.00203.2005